0.3987
Applied Therapeutics Inc stock is traded at $0.3987, with a volume of 1.38M.
It is up +0.10% in the last 24 hours and down -27.42% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.3983
Open:
$0.3956
24h Volume:
1.38M
Relative Volume:
0.57
Market Cap:
$47.09M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.2953
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
+19.73%
1M Performance:
-27.42%
6M Performance:
-95.27%
1Y Performance:
-90.57%
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
APLT
Applied Therapeutics Inc
|
0.3987 | 47.09M | 0 | -119.76M | -55.17M | -1.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
Dec-02-24 | Downgrade | UBS | Buy → Neutral |
Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-31-24 | Initiated | William Blair | Outperform |
Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
Feb-22-24 | Initiated | Leerink Partners | Outperform |
Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
Jun-25-21 | Resumed | Goldman | Neutral |
Oct-08-20 | Initiated | Truist | Buy |
Apr-22-20 | Initiated | Goldman | Buy |
Feb-27-20 | Initiated | Barclays | Overweight |
Jun-10-19 | Initiated | Citigroup | Buy |
Jun-10-19 | Initiated | Cowen | Outperform |
Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Applied Therapeutics Inc (NASDAQ:APLT)’s 12-Month Price Target Is Now Set At 5. - Marketing Sentinel
APLT stock touches 52-week low at $0.3 amid sharp annual decline By Investing.com - Investing.com South Africa
APLT stock touches 52-week low at $0.3 amid sharp annual decline - Investing.com
Applied Therapeutics Reports 2024 Financial Results and Leadership Changes - TipRanks
Applied Therapeutics, Inc. SEC 10-K Report - TradingView
Applied Therapeutics (APLT) Reports Lower Revenue But Reinforces Strategic Focus | APLT Stock News - GuruFocus
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Fi - GuruFocus
Applied Therapeutics earnings beat by $0.71, revenue fell short of estimates - Investing.com Canada
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - The Manila Times
Applied Therapeutics Strengthens Balance Sheet: $79.4M Cash Position Powers Drug Development Push - Stock Titan
Norges Bank Acquires New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics LawsuitAPLT - ACCESS Newswire
APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) should contact The Gross Law Firm about pending Class ActionAPLT - MarketScreener
APLT stock touches 52-week low at $0.42 amid sharp annual decline - Investing.com Australia
Investors Who Lost Money on Applied Therapeutics, Inc. (APLT) Should Contact Levi & Korsinsky About Pending Class ActionAPLT - ACCESS Newswire
APLT stock touches 52-week low at $0.42 amid sharp annual decline By Investing.com - Investing.com South Africa
Applied Therapeutics, Inc. (APLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Class Action Filed Against Applied Therapeutics, Inc. (APLT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
APLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Charles Schwab Investment Management Inc. Has $600,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Delays Yearly Report Filing - TipRanks
Applied Therapeutics files Form 12b-25 with SEC - TipRanks
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire
Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan
146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz
APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News
Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq
Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com
Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat
Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
APPLIED THERAPEUTICS Earnings Preview: Recent $APLT Insider Trading, Hedge Fund Activity, and More - Nasdaq
A look into Applied Therapeutics Inc (APLT)’s deeper side - SETE News
Applied Therapeutics Inc (APLT) Announces Year-End 2023 Financia - GuruFocus.com
40,300 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Private Advisor Group LLC - Defense World
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):